Skip to main content
. 2020 Aug 13;11(1):258–270. doi: 10.1016/j.apsb.2020.08.001

Figure 7.

Figure 7

The antitumor efficacy of various formulations. (A) The experimental scheme of formulations against prostate cancer. (B) Tumor growth curves. (C) Body weight curves. (D) Serum prostate-specific antigen (PSA) levels after treatment. (E) Corresponding survival curves and median survival periods to panel (A). (F) Typical hematoxylin and eosin (H&E) (1) and TUNEL (2) staining of tumor tissues after treatment. In panel E&F, a-Saline, b-Jevtana, c-Lipo SA-CTX 6 mg/kg, d-Lipo SA-CTX 30 mg/kg, e-Lipo GA-CTX 6 mg/kg, f-Lipo GA-CTX 30 mg/kg, g-Lipo DA-CTX 6 mg/kg, h-Lipo DA-CTX 30 mg/kg. Data are shown as the mean ± SD, n = 6, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. Scar bar = 100 μm.